Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Springworks Therapeutics Inc's Business Segments
Springworks Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Developing and Commercializing Life Changing Medicines
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Developing and Commercializing Life Changing Medicines0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Developing and Commercializing Life Changing Medicines | $ 49 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Developing and Commercializing Life Changing Medicines0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Developing and Commercializing Life Changing Medicines | $ 49 | - |
Description of Springworks Therapeutics Inc
Springworks Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing potential new therapies for rare genetic diseases and cancer. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Springworks Therapeutics aims to identify and advance promising investigational therapies by leveraging its strategic collaborations with other biotechnology and pharmaceutical companies. The company combines its expertise in drug development with a focus on precision medicine to tackle challenging diseases.
One of the key areas of focus for Springworks Therapeutics is the treatment of rare genetic diseases caused by changes or mutations in single genes. These genetic disorders often lead to significant medical problems for patients and have limited treatment options. By identifying targeted therapies, Springworks Therapeutics aims to improve the lives of these patients.
Closely associated with this is the development of precision oncology treatments. The company aims to address unmet medical needs in cancer care by developing innovative therapies that target specific genetic alterations or molecular pathways implicated in the growth and progression of cancer.
Springworks Therapeutics is actively involved in multiple clinical trials to evaluate the safety and efficacy of its investigational therapies. The company collaborates with a range of partners, including academic institutions, patient advocacy groups, and other biopharmaceutical companies, to accelerate the development of new therapies.
One of the most significant partnerships for Springworks Therapeutics is with Pfizer, a global pharmaceutical company. The collaboration focuses on developing combination therapies for patients with rare forms of cancer. By pooling resources and expertise, the two companies aim to accelerate the development of potentially life-saving treatments.
In addition to its collaborations, Springworks Therapeutics has a robust internal research and development program. The company leverages its scientific and clinical expertise to identify and validate new therapeutic targets and optimize drug candidates.
Overall, Springworks Therapeutics Inc is a dedicated biopharmaceutical company working towards developing innovative therapies for rare genetic diseases and cancer. Through strategic collaborations, clinical trials, and internal research initiatives, the company aims to improve the lives of patients by providing effective treatments for these challenging diseases.
Springworks Therapeutics aims to identify and advance promising investigational therapies by leveraging its strategic collaborations with other biotechnology and pharmaceutical companies. The company combines its expertise in drug development with a focus on precision medicine to tackle challenging diseases.
One of the key areas of focus for Springworks Therapeutics is the treatment of rare genetic diseases caused by changes or mutations in single genes. These genetic disorders often lead to significant medical problems for patients and have limited treatment options. By identifying targeted therapies, Springworks Therapeutics aims to improve the lives of these patients.
Closely associated with this is the development of precision oncology treatments. The company aims to address unmet medical needs in cancer care by developing innovative therapies that target specific genetic alterations or molecular pathways implicated in the growth and progression of cancer.
Springworks Therapeutics is actively involved in multiple clinical trials to evaluate the safety and efficacy of its investigational therapies. The company collaborates with a range of partners, including academic institutions, patient advocacy groups, and other biopharmaceutical companies, to accelerate the development of new therapies.
One of the most significant partnerships for Springworks Therapeutics is with Pfizer, a global pharmaceutical company. The collaboration focuses on developing combination therapies for patients with rare forms of cancer. By pooling resources and expertise, the two companies aim to accelerate the development of potentially life-saving treatments.
In addition to its collaborations, Springworks Therapeutics has a robust internal research and development program. The company leverages its scientific and clinical expertise to identify and validate new therapeutic targets and optimize drug candidates.
Overall, Springworks Therapeutics Inc is a dedicated biopharmaceutical company working towards developing innovative therapies for rare genetic diseases and cancer. Through strategic collaborations, clinical trials, and internal research initiatives, the company aims to improve the lives of patients by providing effective treatments for these challenging diseases.
Springworks Therapeutics Inc is a biopharmaceutical company dedicated to developing innovative precision medicines aimed at addressing severe genetic diseases and various types of cancer. The company strategically focuses on two primary segments: Rare Genetic Diseases and Oncology, which encompass a robust portfolio of products and services aimed at meeting significant unmet medical needs.
Segments
1. Rare Genetic Diseases
Springworks Therapeutics targets rare genetic diseases typically caused by single-gene defects. These conditions often lack approved treatments, presenting a critical need for effective therapeutic options. The companys focus in this segment involves developing targeted therapies that approach the underlying genetic mutations responsible for these disorders. By leveraging genetic insights and innovative therapeutic approaches, Springworks seeks to correct or mitigate the effects of these genetic anomalies, improving the quality of life for affected patients.
Oncology
In the field of oncology, Springworks Therapeutics is dedicated to developing precision medicine approaches that tailor treatment based on the genetic profile of the cancer. The companys research and development efforts in this segment utilize advanced molecular biology techniques and genomic analyses to identify specific mutations and alterations that facilitate cancer progression. By focusing on these targeting strategies, Springworks aims to develop therapies that effectively inhibit tumor growth while minimizing impact on healthy tissues, thereby enhancing treatment outcomes for patients battling various forms of cancer.
Products and Services
1. Nirogacestat
Nirogacestat is one of the flagship products from Springworks Therapeutics. This investigational therapy is an oral small molecule gamma secretase inhibitor. It aims to counter various cancers alongside selected rare genetic diseases by intervening in specific signaling pathways that are integral to tumor growth and disease progression. Targeting these pathways not only addresses the immediate therapeutic needs but also integrates into the broader effort to personalize treatment strategies based on the molecular characteristics of the disease.
Partnerships and Collaborations
Springworks Therapeutics actively seeks partnerships and collaborations with other pharmaceutical entities, academic institutions, and research organizations. These strategic alliances enable the company to access a broader spectrum of resources, expertise, and innovative technologies, significantly accelerating the development of its therapeutic pipeline. Through these collaborations, Springworks aims to enhance its research capabilities, share knowledge, and improve the efficiency of bringing new therapies to market.
Clinical Trials
The company has established a robust clinical trial program designed to assess the safety, efficacy, and side effects of its investigational therapies. These clinical trials are critical for gathering the necessary evidence to secure regulatory approvals, which ultimately determine the accessibility of these therapies to patients. Springworks is committed to adhering to the highest standards of clinical research, ensuring that its findings contribute to the growing body of knowledge in the field of precision medicine.
Patient Support Programs
In tandem with its therapeutic development efforts, Springworks Therapeutics emphasizes the importance of patient support throughout treatment journeys. The company implements various patient support programs aimed at helping individuals access and afford their prescribed medications. By providing resources such as financial assistance, navigation services, and educational materials, Springworks aims to foster a nurturing environment that prioritizes patient-centered care. The companys commitment to patients extends beyond drug development, recognizing the integral role of support in improving treatment adherence and overall outcomes.
Summary
In conclusion, Springworks Therapeutics Inc operates at the intersection of rare genetic diseases and oncology, offering a diverse range of products and services, including its investigational therapy Nirogacestat. The company exemplifies a commitment to innovative therapeutic development through strategic partnerships, rigorous clinical trials, and a strong emphasis on patient support. With a clear focus on precision medicine, Springworks Therapeutics aims to significantly improve the lives of patients facing challenging health conditions, embodying a forward-thinking approach that seeks to fill critical gaps in current treatment landscapes.
Segments
1. Rare Genetic Diseases
Springworks Therapeutics targets rare genetic diseases typically caused by single-gene defects. These conditions often lack approved treatments, presenting a critical need for effective therapeutic options. The companys focus in this segment involves developing targeted therapies that approach the underlying genetic mutations responsible for these disorders. By leveraging genetic insights and innovative therapeutic approaches, Springworks seeks to correct or mitigate the effects of these genetic anomalies, improving the quality of life for affected patients.
Oncology
In the field of oncology, Springworks Therapeutics is dedicated to developing precision medicine approaches that tailor treatment based on the genetic profile of the cancer. The companys research and development efforts in this segment utilize advanced molecular biology techniques and genomic analyses to identify specific mutations and alterations that facilitate cancer progression. By focusing on these targeting strategies, Springworks aims to develop therapies that effectively inhibit tumor growth while minimizing impact on healthy tissues, thereby enhancing treatment outcomes for patients battling various forms of cancer.
Products and Services
1. Nirogacestat
Nirogacestat is one of the flagship products from Springworks Therapeutics. This investigational therapy is an oral small molecule gamma secretase inhibitor. It aims to counter various cancers alongside selected rare genetic diseases by intervening in specific signaling pathways that are integral to tumor growth and disease progression. Targeting these pathways not only addresses the immediate therapeutic needs but also integrates into the broader effort to personalize treatment strategies based on the molecular characteristics of the disease.
Partnerships and Collaborations
Springworks Therapeutics actively seeks partnerships and collaborations with other pharmaceutical entities, academic institutions, and research organizations. These strategic alliances enable the company to access a broader spectrum of resources, expertise, and innovative technologies, significantly accelerating the development of its therapeutic pipeline. Through these collaborations, Springworks aims to enhance its research capabilities, share knowledge, and improve the efficiency of bringing new therapies to market.
Clinical Trials
The company has established a robust clinical trial program designed to assess the safety, efficacy, and side effects of its investigational therapies. These clinical trials are critical for gathering the necessary evidence to secure regulatory approvals, which ultimately determine the accessibility of these therapies to patients. Springworks is committed to adhering to the highest standards of clinical research, ensuring that its findings contribute to the growing body of knowledge in the field of precision medicine.
Patient Support Programs
In tandem with its therapeutic development efforts, Springworks Therapeutics emphasizes the importance of patient support throughout treatment journeys. The company implements various patient support programs aimed at helping individuals access and afford their prescribed medications. By providing resources such as financial assistance, navigation services, and educational materials, Springworks aims to foster a nurturing environment that prioritizes patient-centered care. The companys commitment to patients extends beyond drug development, recognizing the integral role of support in improving treatment adherence and overall outcomes.
Summary
In conclusion, Springworks Therapeutics Inc operates at the intersection of rare genetic diseases and oncology, offering a diverse range of products and services, including its investigational therapy Nirogacestat. The company exemplifies a commitment to innovative therapeutic development through strategic partnerships, rigorous clinical trials, and a strong emphasis on patient support. With a clear focus on precision medicine, Springworks Therapeutics aims to significantly improve the lives of patients facing challenging health conditions, embodying a forward-thinking approach that seeks to fill critical gaps in current treatment landscapes.